Your shopping cart is currently empty

USP7-797 is a selective non-covalent active site USP7 inhibitor, inhibiting USP7 and ubiquitin binding, with anti-tumor, oral and high efficiency (IC50=0.44 nmol), it is effective on both wild-type and mutant p53 tumor cells, and can significantly inhibit the growth of tumor cells and induce apoptosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $385 | In Stock | In Stock | |
| 5 mg | $888 | In Stock | In Stock | |
| 10 mg | $1,420 | - | In Stock | |
| 25 mg | $2,420 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $996 | - | In Stock |
| Description | USP7-797 is a selective non-covalent active site USP7 inhibitor, inhibiting USP7 and ubiquitin binding, with anti-tumor, oral and high efficiency (IC50=0.44 nmol), it is effective on both wild-type and mutant p53 tumor cells, and can significantly inhibit the growth of tumor cells and induce apoptosis. |
| In vitro | Methods: USP7-797 (0-1 μM) was used to treat p53 wild-type hematological cancer cell lines, and cell viability was determined. Results: USP7-797 was cytotoxic to p53 wild-type hematological cancer cell lines, with CC50 values of 0.2, 0.2, 0.4, and 0.1 μM for M07e, OCI-AML5, MOLM13, and MM.IS, respectively. Methods: USP7-797 (0-25 μM) was used to treat p53 mutant cancer cell lines, and cell viability was determined. Results: USP7-797 was cytotoxic to p53 mutant cancer cell lines, with CC50 values of 0.5, 0.2, and 0.2 μM for H526, LA-N-2, and SK-N-DZ, respectively. Methods: USP7-797 (0-2 μM) was used to treat p53 wild-type neuroblastoma cell lines and cell viability was measured. Results: USP7-797 was cytotoxic to p53 wild-type neuroblastoma cell lines, with CC50 values of 1.9, 0.6, and 0.5 μM for SH-SY5Y, CHP-134, and NB-1, respectively. [1] |
| Synonyms | USP7-IN-7, USP7797, USP 7-797 |
| Molecular Weight | 510.05 |
| Formula | C27H28ClN3O3S |
| Cas No. | 2413944-70-2 |
| Smiles | CC1(C)C2C1C(=O)N(CC=3SC=4C(C3)=NC=CC4C5=C(C[C@@H]6CNCCO6)C(C)=CC(Cl)=C5)C2=O |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (117.64 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.